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Prevalence, Characteristics, and Clinical Course
of Neuropathic Pain in Primary Care Patients
Consulting With Low Back-related Leg Pain
Sarah A. Harrisson, PhD,*† Reuben Ogollah, PhD,‡ Kate M. Dunn, PhD,*
Nadine E. Foster, DPhil,* and Kika Konstantinou, PhD*†
Objectives: Little is known about the epidemiology of neuropathic
pain in primary care patients consulting with low back-related leg
pain. We aimed to describe prevalence, characteristics, and clinical
course of low back-related leg pain patients with and without
neuropathic pain, consulting with their family doctor in the United
Kingdom.
Materials and Methods: This was a prospective cohort study. Data
were collected using a standardized baseline clinical examination
and self-report questionnaires at baseline, 4, 12, and 36 months. We
identified cases of neuropathic pain using 3 definitions: 2 based on
clinical diagnosis (sciatica, with and without evidence of nerve root
compression on magnetic resonance imaging), one on the self-report
version of Leeds Assessment for Neurological Symptoms and Signs.
Differences between patients with and without neuropathic pain
were analyzed comparing each definition. Clinical course (mean
pain intensity measured as the highest of leg or back pain intensity:
mean of 3 Numerical Rating Scales, each 0 to 10) was investigated
using linear mixed models over 36 months.
Results: Prevalence of neuropathic pain varied from 48% to 74%
according to definition used. At baseline, patients with neuropathic
pain had more severe leg pain intensity, lower pain self-efficacy,
more patients had sensory loss than those without. Distinct profiles
were apparent depending on neuropathic pain definition. Mean pain
intensity reduced after 4 months (6.1 to 3.9 [sciatica]), most rapidly
in cases defined by clinical diagnosis.
Discussion: This research provides new information on the clinical
course of neuropathic pain and a better understanding of neuro-
pathic pain in low back-related leg pain patients consulting in
primary care.
Key Words: low back pain, leg pain, primary care, neuropathic
pain, epidemiology
(Clin J Pain 2020;36:813–824)
N europathic pain (NP), defined as pain caused by injuryor disease of the somatosensory system,1 is considered
to be challenging to manage. The symptoms of NP, which
may include feelings of burning, electric-shock and/
or prickling,2 can be very distressing for patients. There is
no gold standard for defining cases of NP but there is
some consensus for a hierarchical grading system to assist
researchers and clinicians to identify cases of NP.1
Patients with a pain condition, plausible clinical history
and with relevant findings from neurological examination
meet the criteria for having “possible” NP. With the
addition of appropriate findings from diagnostic tests,
patients meet the criteria for having “probable” NP. The
majority of patients with NP are managed in primary
care,3 even if consulting with severe and bothersome pain.
In primary care, where clinicians are nonspecialists, NP
screening tools (eg, self-report version of Leeds Assess-
ment of Neuropathic Symptoms and Signs (s-LANSS)4
have been suggested as useful to identify patients with
possible NP.5
Low back pain (LBP) is thought to be one of the most
common NP presentations6 and is the leading cause of dis-
ability globally.7 Leg pain related to back pain (LBLP) is one
of the most common presentations of LBP8,9 and is associated
with increased pain, disability and poorer quality of life
compared with LBP alone.10 For this reason there is an
argument that LBLP patients should be considered as distinct
for research purposes from those with LBP.11 LBLP is clin-
ically diagnosed as having sciatica (also termed lumbar spinal
nerve root pain or radicular pain) or referred leg pain, where
sciatica is thought to be neuropathic12 and referred leg pain to
be nociceptive.
There are specific pharmacological and nonpharma-
cological treatments (physiotherapy, cognitive behavioral
therapy) available to LBLP patients with and without NP in
primary care. Guidelines advocate that NP medications are
considered for patients with sciatica.13,14 A diagnostic
approach is important when it enables the provision of timely
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and targeted interventions as in acute illnesses, it is not clear
whether this approach is useful for LBLP patients consulting
in primary care. For many LBLP patients consulting in pri-
mary care, identifying NP does not provide sufficient knowl-
edge or evidence of likely future health outcomes.15 It is
widely thought that LBLP patients with NP do worse over
time compared with those without, but evidence from a recent
systematic review16 highlighted the paucity of evidence
describing the prognosis of LBLP patients with NP consulting
in primary care.
The aims of this study were to describe: (1) prevalence
of NP in LBLP patients consulting in primary care; (2)
characteristics of LBLP patients with NP; (3) the clinical
course of LBLP patients with NP at baseline in terms of
pain intensity over short, intermediate, and long-term time-
points. Given there is no perfect standard for identifying
cases of NP, we provide and compare data on prevalence,
characteristics and clinical course, by describing cases using
clinical definitions for NP and also a NP screening tool.
MATERIALS AND METHODS
Study Design and Patient Recruitment
This is secondary analysis of a prospective, multicentre
cohort study, the Assessment and Treatment of Leg pain
Associated with the Spine (ATLAS) study, of LBLP patients
consulting and receiving treatment in primary care. Ethical
approval was granted by the South Birmingham Research
Ethics Committee (REC ref10/H1207/82) in October 2010
for the original study, and by NRES Committees North of
Scotland (REC ref13/NS/0170) for the longer-term follow-
up. All analyses in this report were nested within this pro-
gram of work. Adults aged 18 years and over with LBLP of
any duration and severity, who consulted with their family
doctor, were invited to take part in the ATLAS study. For
the full details of the recruitment procedure see the ATLAS
study protocol,17 the flow of patients in the ATLAS study is
summarized in Figure 1. Patients were considered to have
LBLP if they presented with leg pain that spread from the
lower back beyond the gluteal fold to anywhere in the leg.
Pain was considered to include unpleasant sensations such
as pins and needles or numbness. Patients were excluded if
there was suspected serious spinal pathology, previous spi-
nal surgery, pregnancy, they were receiving physiotherapy
treatment (or osteopathy or chiropractic) or were under the
care of a specialist consultant in secondary care for the same
condition, those with serious physical or mental comorbidity
that would prevent them attending the research clinic or
undergoing the study’s procedures, or inability to read and
speak English.
All participants in the study were assessed by physi-
otherapists and a neurological examination was carried out as
part of the clinical examination as recommended in LBP
guidelines19 and specialist books (eg, Examination of the
Lumbar Region in Neuromusculoskeletal Examination and
Assessment, pages 329 to 330).20 At the time of the clinical
examination, a clinical diagnosis of either sciatica or referred
leg pain was made. In this research, a clinical diagnosis of
sciatica was characterized by leg pain that may radiate to
beyond the knee and into the foot or toes, and may be
accompanied by muscle weakness and/or reflex change and/or
pins and needles or numbness (paresthesia), in a specific nerve
root(s) distribution.21 The term sciatica is indicative of nerve
root compression (NRC) causing radicular pain with or
without neurological deficits and the criteria for clinical
diagnosis was predetermined following consensus from a
Delphi study.22
All physiotherapists in the ATLAS study were given
training in the study’s procedures. There was fair agreement
between physiotherapists in this study when making a
diagnosis of sciatica or referred leg pain. The full details of
the agreement and reliability among the clinicians in the
ATLAS study when diagnosing low back-related leg pain
are provided elsewhere.23 All patients in the ATLAS study
were invited for a magnetic resonance imaging (MRI) scan
within 10 days of attending their assessment at the ATLAS
research clinic, except in cases where this imaging was
contraindicated, or when the patient did not wish to have a
scan, or when an MRI scan was already available in the
previous 6 months for the same clinical presentation. Data
used in this analysis were collected at baseline and at 3
follow-up points at 4 months, 12 months, and 3 years using
postal self-complete questionnaires.
Treatment Pathways
Treatment plans for patients in the study were agreed
between the treating physiotherapist and the patient, and
FIGURE 1. Study flow diagram (adapted from Konstantinou
et al18). Adaptations are themselves works protected by copy-
right. So in order to publish this adaptation, authorization must
be obtained both from the owner of the copyright in the original
work and from the owner of copyright in the translation or
adaptation. MRR indicates medical records review; s-LANSS, self-
report version of Leeds Assessment for Neurological Symptoms
and Signs.
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according to current best clinical evidence and practice
guidelines. For those patients where physiotherapy man-
agement was indicated, up to 6 (on average) treatment ses-
sions (of 30 min) were delivered over 6 to 8 weeks. If a
patient’s symptoms worsened or failed to improve, path-
ways were in place so that appropriate referrals could be
made to specialist spinal services for further assessment and
management including onward referral to spinal surgeons
and pain specialists.
Selected Characteristics of Interest
The characteristics chosen to describe LBLP patients
with and without NP were based on sociodemographic
information (age, sex, socioeconomic status based on type of
work, smoking status and body mass index), health status
(presence of diabetes, general health,24 fatigue, and sleep
difficulties), information about pain (mean back pain
intensity, mean leg pain intensity,25 pain described as
burning, duration of pain, pain location, presence of wide-
spread pain), limitations in activities (back and leg pain
related disability using the Roland and Morris Disability
Questionnaire)26 leg version,27 psychological variables
(symptoms of depression and anxiety using the Hospital
Anxiety and Depression Scale28), pain self-efficacy beliefs
using the Pain Self-Efficacy Questionnaire,29 findings from
neurological examination (presence of muscle weakness,
tendon reflex, sensation to pin prick, presence of pins and
needles, pain affecting the color of patients skin, presence of
allodynia or hyperalgesia in the leg(s), neural tension test
and imaging using MRI), and the number of pain medi-
cations used. See Table S1 (Supplemental Digital Content 1,
http://links.lww.com/CJP/A685), for full details of all the
characteristics collected in this study.
Data Analysis
Cases of NP were identified using 3 definitions of NP: 2
based on clinical diagnosis (sciatica21,22 with and without
evidence of NRC on MRI), one on the self-report using
s-LANSS4 (see Table 1 for a detailed description of each of
the 3 definitions of NP used in this research). Prevalence was
estimated for 3 definitions of NP. Descriptive statistics (mean
and SD for continuous variables and frequency and
percentage for categorical variables) were used to describe
characteristics of interest in those with NP for each of the NP
definitions. Logistic regression was used to examine the
association between NP (based on the 3 definitions), charac-
teristics of interest and was based on the analysis of
complete cases.
For describing the clinical course, linear mixed models,
with a NP indicator variable (according to NP definition used)
by time interaction, were used to estimate the unadjusted mean
and 95% confidence intervals (CIs) of pain intensity at all 3
follow-up time-points. CIs were obtained to evaluate the
uncertainty of estimates taking into account the missing data.30
Margins plots were used to graphically summaries the infor-
mation on the clinical course.
All statistical analyses were performed using Stata
version 14.0.31 The STrengthening the Reporting of
OBservational studies in Epidemiology (STROBE) checklist
for cohort studies was used when writing the report.32
Measures of Clinical Course
Pain intensity scores at baseline, 4 months, 12 months,
and 3 years, were used to describe the clinical course of this
patient population. Pain intensity was determined as the
highest of mean leg pain intensity or mean back pain
intensity in the previous 2 weeks, where leg pain intensity
was determined as the mean of three 0 to 10 NRS for cur-
rent, usual and least leg pain over the previous 2 weeks, and
back pain intensity as the mean of current, usual and least
back pain over the previous 2 weeks.25
RESULTS
Study Population
In total, 609 patients with LBLP were eligible and
consented to participate in the study; patients received a
clinical diagnosis of either referred leg pain or sciatica and
554 had an MRI. Three of 609 patients did not complete all
7 items of the s-LANSS. In total, 402 (66.0%) completed the
study questionnaire at 4 months, 450 (73.9%) at 12 months,
and 316 (51.9%) at 3 years. Patients who responded to fol-
low-up at 4 months were older than nonresponders (mean
54 y compared with 42 y), fewer scored 12 or greater on
s-LANSS (45% compared with 55%), a slightly higher pro-
portion had a clinical diagnosis of sciatica (77% compared
with 70%) and they had slightly lower LBLP-related dis-
ability (mean Roland and Morris Disability Questionnaire
12.1 compared with 13.7) at baseline. This was consistent at
12 months and 3 years. Nearly 9 of 10 (88.0%) patients in
the ATLAS cohort received a course of physiotherapy
treatment and 11.4% of patients were referred to specialist
services for further treatment or investigations. A slightly
higher proportion (14.3%) of patients with NP based on a
clinical diagnosis of sciatica with evidence NRC were
referred for an epidural injection or to spinal surgeons.
Table S2 (Supplemental Digital Content 2, http://links.lww.
com/CJP/A686) gives details on the care provided to
patients in the ATLAS study according to the 3 definitions
of NP.
Prevalence of NP in LBLP Patients
The prevalence of NP was 74.2% based on a clinical
diagnosis of sciatica (452/609), 48.8% based on s-LANSS
(296/606), and 45.5% based on sciatica with evidence of
possible or clear NRC (252/554). Just under one quarter
(23.0%, 127/551) of LBLP patients were defined as having
TABLE 1. Methods Used to Identify Cases of Neuropathic Pain
Approach Description of Definition
Level of
Certainty
Clinical
examination
Clinical diagnosis of sciatica* with
evidence of possible or clear
nerve root compression on MRI
scan
Probable†
Clinical
examination
Clinical diagnosis of sciatica*
without evidence of nerve root
compression on MRI scan
Possible†
Neuropathic pain
screening tool
S-LANSS score of≥ 12 Possible‡
Clinical
examination
Clinical diagnosis of referred leg
pain
Unlikely†
*Described by Koes et al21 criteria for clinical diagnosis agreed by con-
sensus by Konstantinou et al.22
†Described by Treede et al1 and later updated by Finnerup et al.14
‡Described by Smith et al.5
MRI indicates magnetic resonance imaging; s-LANSS, self-report ver-
sion of Leeds Assessment for Neurological Symptoms and Signs.
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NP using all 3 definitions. Nearly 4 in 10 patients (38.3%,
232/606) were defined as having NP based on s-LANSS and
clinical diagnosis of sciatica. Around 1 in 10 (10.7%, 61/606)
were defined as having NP based on s-LANSS, but were not
by clinical diagnosis of sciatica either with or without evi-
dence of NRC. The distributions and overlap of LBLP
patients with or without NP, based on the 3 definitions, are
summarized in Figure 2.
Characteristics of LBLP Patients With NP
The profile of patients with NP based on s-LANSS was
quite distinct compared with those without; they were more
often current smokers, presented with more severe back pain
intensity, more scored higher for depression and anxiety, more
had an increased response to either nonpainful or painful
stimuli on clinical examination and more often used 2 or more
pain medications compared with those without NP. The
profile of patients with neuropathic LBLP based on s-LANSS
was also quite distinct compared with those with NP based on
clinical diagnosis of sciatica either with or without evidence of
NRC on MRI. There were few differences in terms of health
status, limitations in activities, psychological variables, and
pain medication use between patients with NP based on
clinical diagnosis of sciatica compared with those more
stringently defined as having a clinical diagnosis of sciatica
with evidence of NRC based on MRI.
The characteristics of LBLP patients with and without
NP based on s-LANSS, those with NP based on a clinical
diagnosis of sciatica, and those with LBLP based on clinical
diagnosis of sciatica plus evidence of possible or clear NRC
on MRI, respectively are provided in Tables 2–4. LBLP
patients with NP, across all 3 NP definitions, reported more
severe leg pain (for a 1-unit increase in NRS score for leg
pain intensity, the odds [95% CI] presenting with NP based
on s-LANSS increased by 1.20 [1.12, 1.29], the odds of
having a clinical diagnosis of sciatica increased by 1.32
[1.21, 1.44] and the odds of having a clinical diagnosis of
sciatica plus evidence of NRC based on MRI increased by
1.29 [1.19, 1.40]); patients with pain below the knee were
more likely to present with NP compared with those without
with the odds ratios (95% CI) of 1.98 (1.38, 2.87), 9.03 (6.00,
13.60), and 4.18 (2.74, 6.37) for definition based on
s-LANSS, clinical diagnosis of sciatica and clinical diag-
nosis of sciatica plus evidence of NRC based on MRI,
respectively; and more had a weaker belief in the ability to
cope with normal activities despite the pain (pain self-effi-
cacy) compared with those without (for a 1 unit decrease in
Pain Self-Efficacy Questionnaire score, the odds of pre-
senting with NP based on s-LANSS increased by 0.97 (0.97,
0.98), by 0.98 (0.98, 0.997) for those with a clinical diagnosis
of sciatica and by 0.98 (0.97, 0.99) for those with a clinical
diagnosis of sciatica plus evidence of NRC based on MRI).
On the basis of findings from neurological examination
and consistently across all 3 definitions of NP, patients with a
reduction in sensation to pin-prick were more likely to present
with NP (odds ratios [95% CI] 1.64 [1.16 to 2.33], 3.87 [2.43,
6.16], 1.76 [1.22, 2.54] for definition based on s-LANSS,
clinical diagnosis of sciatica and clinical diagnosis of sciatica
plus evidence of NRC based on MRI, respectively) and those
with a significant reduction or absence of tendon reflex (odds
ratios [95% CI] 1.68 [1.06, 2.65], 4.42 [2.09, 9.38], 5.63 [3.22,
9.86] for definition based on s-LANSS, clinical diagnosis of
sciatica and clinical diagnosis of sciatica plus evidence of
NRC based on MRI, respectively) were more likely to present
with NP compared with those without. The presence of mild
muscle weakness (myotomal) was found in 100% of patients
with a clinical diagnosis of sciatica with or without evidence of
NRC on MRI, and was associated with those patients with
NP based on s-LANSS.
Clinical Course
Pain intensity decreased over time and most of the
change occurred between baseline and 4 months, irrespective
of the NP case definition used. Mean pain intensity in patients
with NP at baseline (across the 3 definitions) ranged from 6.1
to 6.3, decreasing to between 3.8 and 4.3 at 4 months
(Figs. 3A–C). Improvement in pain intensity plateaued
around 4 months and changed very little up to 36 months for
all NP definitions (mean pain intensity of patients with NP at
3 years ranged from 3.3 to 3.9 for the 3 definitions).
Patients with NP (based on s-LANSS) had higher mean
pain intensity (95% CI) compared with those without at
12 months (4.4 [4.1, 4.7] vs. 3.0 [2.7, 3.3]), but not at 3 years (3.9
[3.5, 4.3] vs. 3.0 [2.7, 3.4]). Patients with NP (based on a clinical
diagnosis of sciatica) had lower mean pain intensity compared
with those without at 12 months (3.6 [3.3, 3.8] vs. 4.0 [3.5, 4.4])
and at 3 years (3.3 [3.1, 3.6] vs. 3.8 [4.4, 4.3]). Those patients
with sciatica plus MRI evidence of NRC had lower mean pain
intensity at 4 months (3.8 [3.5, 4.2] vs. 4.1 [3.8, 4.3]), 12-months
(3.3 [3.0, 3.7] vs. 4.0 [3.7, 4.4]), and 3 years (3.3 [3.9, 3.6] vs. 3.6
[3.2, 4.0]).
DISCUSSION
This is the first prospective cohort including LBLP
patients consulting in primary care with NP, and the first time
that data on the clinical course of neuropathic LBLP over
short, intermediate, and long-term time-points, has been
reported. Prevalence estimates of NP in this patient population
varied from 48% to 74% depending on the NP definition used.
Irrespective of case definition, our study shows that the pres-
ence of NP in LBLP patients consulting in primary care, is
Sciatica with evidence
of clear or possible
NRC on MRI
Sciatica
S-LANSS ≥ 12
Referred leg
pain
23%
23%
12%
15% 11% 16%
FIGURE 2. Venn diagram depicting the overlap between patients
with and without neuropathic pain at baseline based on 3 case
definitions. MRI indicates magnetic resonance imaging; NRC,
nerve root compression; s-LANSS, self-report version of Leeds
Assessment for Neurological Symptoms and Signs.
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TABLE 2. Baseline Characteristics of Patients With Neuropathic Pain Based on s-LANSS
Neuropathic Pain (s-LANSS≥ 12)
Characteristics*
Yes, n= 293
(48.4%)
No, n= 313
(51.7%)
Unadjusted Odds Ratio
(95% CI)
Sociodemographic characteristics
Female (n= 606) 200 (68.3) 182 (58.2) 1.55 (1.10, 2.16)
Age (n= 606), mean (SD) 49.8 (13.5) 50.4 (14.2) 1.00 (0.99, 1.01)
Socioeconomic status (n= 590)
Higher managerial, administrative and professional occupations 49 (17.4) 79 (25.7) 1
Intermediate occupations 71 (25.2) 86 (27.9) 1.33 (0.83, 2.14)
Routine and manual occupations 142 (50.4) 140 (45.5) 1.64 (1.07, 2.5)
Never worked and long-term unemployed 20 (7.1) 3 (1.0) 10.75 (3.03, 38.07)
Smoking status (n= 605)
Never 99 (33.9) 127 (40.6) 1
Ex-smoker 80 (27.4) 105 (33.6) 0.98 (0.66, 1.45)
Current 113 (38.7) 81 (25.9) 1.79 (1.21, 2.64)
BMI (n= 598), mean (SD)
(kg/m2)
29.7 (6.1) 29.5 (5.6) 1.01 (0.98, 1.03)
Health status
Self-reported diabetes (n= 606) 25 (8.5) 22 (7.0) 1.23 (0.68, 2.24)
Self-reported general health (n= 605)
Excellent/very good 52 (17.8) 93 (29.7) 1
Good 93 (31.9) 78 (24.9) 2.13 (1.35, 3.36)
Fair 116 (39.7) 123 (39.3) 1.69 (1.10, 2.58)
Poor 31 (10.6) 19 (6.1) 2.92 (1.50, 5.67)
Fatigue (n= 593) 214 (74.3) 198 (64.9) 1.56 (1.10, 2.23)
Sleep difficulties (n= 601) 258 (88.4) 253 (81.9) 1.68 (1.06, 2.66)
Pain characteristics
Back pain intensity (0-10) (n= 600), mean (SD) 5.5 (1.6) 5.1 (1.6) 1.15 (1.04, 1.27)
Leg pain intensity (0-10) (n= 578), mean (SD) 5.8 (2.3) 4.7 (2.4) 1.20 (1.12, 1.29)
Constant pain symptoms (n= 594) 221 (75.4) 177 (58.8) 2.15 (1.51, 3.06)
Pain described as burning pain (n= 606) 165 (56.3) 55 (17.6) 6.05 (4.18, 8.77)
Duration of back pain symptoms in current episode (n= 604)
< 6 wk 98 (33.7) 119 (38.0) 1
6-12 wk 65 (22.3) 60 (19.2) 1.32 (0.87, 2.04)
> 3mo 128 (44.0) 134 (42.8) 1.16 (0.81, 1.66)
Duration of leg pain symptoms in current episode (n= 580)
< 6 wk 110 (39.3) 141 (47.0) 1
6-12 wk 61 (21.8) 58 (19.3) 1.18 (0.75, 1.86)
> 3mo 109 (38.9) 101 (33.7) 1.41 (0.96, 2.08)
Widespread pain† (n= 590) 124 (42.9) 125 (41.5) 1.05 (0.74, 1.47)
Leg pain worse (n= 604) 138 (47.4) 139 (44.4) 1.13 (0.82, 1.56)
Pain location (n= 606)
Pain below the knee 228 (77.8) 200 (63.9) 1.98 (1.38, 2.87)
Pain in 1 leg 211 (72.0) 244 (78.0) 0.73 (0.50, 1.06)
Limitations in activities, participation and risk of persistent disabling pain, mean (SD)
LBLP-related disability (RMDQ, 0-23) (n= 606) 13.8 (5.6) 11.5 (5.6) 1.08 (1.05, 1.11)
Risk of persistent disability due to back pain (STarT Back) (n= 530)
Low risk 29 (10.2) 53 (17.6) 1
Medium risk 120 (42.3) 154 (51.0) 1.57 (0.92, 2.7)
High risk 135 (47.5) 95 (31.5) 2.7 (1.56, 4.7)
Psychological characteristics
Depression (HADS) (n= 606)
Normal (0-7) 155 (52.9) 235 (75.1) 1
Possible (mild) cases (8-10) 67 (22.9) 52 (16.6) 1.95 (1.29, 2.96)
Probable (moderate/severe) cases (≥ 11) 71 (24.2) 26 (8.3) 4.14 (2.53, 6.78)
Anxiety (HADS) (n= 604)
Normal (0-7) 118 (40.6) 196 (62.6) 1
Possible (mild) cases (8-10) 60 (20.6) 60 (19.2) 1.66 (1.08, 2.54)
Probable (moderate/severe) cases (≥ 11) 113 (38.8) 57 (18.2) 3.30 (2.22, 4.87)
Pain self-efficacy (PSEQ, 0-60)‡ (n= 590), mean (SD) 30.8 (14.6) 37.4 (13.8) 0.97 (0.96, 0.98)
Neurological examination findings
Muscle strength§ (n= 606)
5/5 231 (78.8) 270 (86.3) 1
4/5 56 (19.1) 36 (11.5) 1.81 (1.15, 2.86)
0 to 3/5 6 (2.1) 7 (2.2) 1.00 (0.33, 3.02)
(Continued )
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common. LBLP patients with NP based on s-LANSS pre-
sented with a more severe profile overall compared with those
with NP based on a clinical diagnosis of sciatica with
or without MRI evidence of NRC. We found several charac-
teristics that were common across the 3 definitions of NP;
higher leg pain intensity, lower pain self-efficacy, higher pro-
portion of patients with pain below the knee, sensory deficits in
the painful leg, mild muscle weakness (myotomal) and reduc-
tion in reflex. On average, there was early improvement in the
clinical course in terms of pain intensity reduction followed by a
plateau, with clinical course being worse only for those patients
with NP identified using the s-LANSS compared with those
without.
Many patients with NP defined by a diagnosis of sciatica
were not identified as having NP based on s-LANSS. This
finding is consistent with previous literature reporting that
many patients with NP based on a clinical diagnosis of scia-
tica were not identified as having NP based on NP screening
tools such as PainDETECT and DN4.16,33 Screening tools
such as s-LANSS which are completed by self-report and
where higher scores indicate the possible presence of NP, may
not be representative of underlying neuropathic mechanisms
specifically, in these patients with sciatica.
This research provides the highest quality evidence to
date on the characteristics of this patient population. As
expected, the characteristics of patients with NP varied
depending on the method used to define cases. Patients with
NP based on s-LANSS presented with a distinctly different
profile compared with those with NP based on clinical
diagnosis of sciatica. Depression, anxiety and use of 2 or
more pain medications were more common in patients with
NP based on s-LANSS compared with those with NP based
on clinical diagnosis of sciatica with or without MRI evi-
dence of NRC. This is consistent with previous research of
patients with and without NP based on clinical
examination,33–35 which found fewer differences in pain
duration, LBLP-related disability, depression, anxiety, and
health-related quality of life between patients with and
without NP compared with those research studies using
screening tools to identify cases of NP.36–38 None of the
previous studies33–38 aimed to describe the characteristics of
LBLP patients with or without NP and, in part, were limited
by either small sample sizes or poorly defined comparator
groups.
The clinical course of patients with and without NP at
baseline, in terms of pain intensity, showed some consistent
similarities across the 3 NP definitions used. On average,
most improvement in pain intensity occurred between
baseline and 4 months, followed by a plateau through to
3 years. This pattern of mean improvement is similar to the
clinical course of LBP patients39 and patients with other
musculoskeletal pain conditions.40
TABLE 2. (continued)
Neuropathic Pain (s-LANSS≥ 12)
Characteristics*
Yes, n= 293
(48.4%)
No, n= 313
(51.7%)
Unadjusted Odds Ratio
(95% CI)
Reflex (tendon) change (n= 606)
None 222 (75.8) 265 (84.7) 1
Slightly reduced 19 (6.5) 11 (3.5) 2.06 (0.96, 4.43)
Significantly reduced or absent 52 (17.8) 37 (11.8) 1.68 (1.06, 2.65)
Sensation to pin-prick in the leg(s) (n= 606)
Normal 150 (51.2) 204 (65.2) 1
Reduction or loss to pin-prick 143 (48.8) 109 (34.8) 1.78 (1.29, 2.47)
Presence of allodynia or hyperalgesia in the leg(s)ǁ (n= 606) 40 (13.7) 17 (5.4) 2.75 (1.52, 4.97)
Neural tension test¶
(any positive test, n= 606)
168 (57.3) 165 (52.7) 1.21 (0.87, 1.66)
Pins and needles in the leg(s) (n= 606) 209 (71.3) 84 (28.7) 5.80 (4.08, 8.23)
Pain affects the color of patients skin (n= 606) 61 (20.8) 6 (1.9) 13.45 (5.70, 31.7)
Neuroimaging
Clear or possible nerve root compression (n= 551) 142 (52.8) 154 (54.6) 0.93 (0.66, 1.30)
Pain medications
No. pain medications# (n= 606)
None 34 (11.6) 49 (15.7) 1
One 103 (35.2) 141 (45.1) 1.05 (0.63, 1.75)
Two or more 156 (53.2) 123 (39.3) 1.83 (1.11, 3.01)
Figures are frequencies (percentages) unless stated otherwise as mean (SD).
Odds ratio (CIs) in italics characteristics associated with neuropathic pain.
*Denominator varies for some characteristics due to missing data or not applicable case.
†Widespread pain was defined as pain present above and below the waist, in the right-hand and left-hand sides of the body and in the axial skeleton.
‡Higher scores on PSEQ reflect stronger self-efficacy beliefs.
§Muscle strength was tested according to a 6-point grading scale where; 0. No visible flicker of movement or contraction. 1. Flicker of movement. 2. Full
active movement with gravity counterbalanced. 3. Full active movement against gravity but not applied resistance. 4. Full active movement against gravity and
some applied resistance. 5. Full active movement against gravity and strong resistance.
ǁHyperalgesia is an increased pain response to painful stimuli. Allodynia is pain response to nonpainful stimuli (eg, brush strokes).
¶Neural tension tests; straight leg raise, femoral stretch and slump test.
#Pain medications include self-reported history of prescribed medications and those purchased over the counter.
BMI indicates body mass index; CI, confidence intervals; HADS, Hospital Anxiety and Depression Scale; LBLP, leg pain related to back pain; PSEQ, Pain
Self-Efficacy Questionnaire; RMDQ, Roland Morris Disability Questionnaire leg version; S-LANSS, self-report version of Leeds Assessment for Neurological
Symptoms and Signs neuropathic pain scale.
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TABLE 3. Baseline Characteristics of Patients With Neuropathic Pain Defined by Clinical Diagnosis of Sciatica
Neuropathic Pain
(Clinical Diagnosis of Sciatica)
Characteristics*
Yes, n= 452
(74.2%)
No, n= 157
(25.8%)
Unadjusted Odds Ratio
(95% CI)
Sociodemographic characteristics
Female (n= 609) 277 (61.3) 106 (67.52) 0.76 (0.52, 1.12)
Age (n= 609), mean (SD) 50.4 (14.0) 49.5 (13.7) 1.01 (0.99, 1.02)
Socioeconomic status (n= 593)
Higher managerial, administrative, and professional occupations 89 (20.3) 40 (25.8) 1
Intermediate occupations 120 (27.4) 38 (24.5) 1.42 (0.84, 2.39)
Routine and manual occupations 210 (48.0) 73 (47.1) 1.29 (0.82, 2.04)
Never worked and long-term unemployed 18 (4.3) 4 (2.6) 2.13 (1.68, 6.68)
Smoking status (n= 608)
Never 169 (37.5) 58 (36.9) 1
Ex-smoker 131 (29.1) 56 (35.7) 0.80 (0.52, 1.24)
Current 151 (33.5) 43 (27.4) 1.21 (0.77, 1.89)
BMI (n= 601), mean (SD) (kg/m2) 29.8 (6.0) 29.1 (5.6) 1.02 (0.99, 1.05)
Health status
Self-reported diabetes (n=608) 37 (8.2) 11 (7.0) 1.18 (0.59, 2.38)
Self-reported general health (n= 608)
Excellent/very good 111 (24.6) 35 (22.3) 1
Good 124 (27.5) 48 (30.6) 0.81 (0.49, 1.35)
Fair 177 (39.3) 63 (40.1) 0.89 (0.55, 1.43)
Poor 39 (8.7) 11 (7.0) 1.12 (0.52, 2.41)
Fatigue (n= 593) 214 (74.3) 198 (64.9) 1.18 (0.79, 1.78)
Sleep difficulties (n= 604) 385 (85.8) 129 (83.2) 0.82 (0.50, 1.36)
Pain characteristics
Back pain intensity (0-10) (n= 603), mean (SD) 5.3 (1.6) 5.3 (1.6) 0.98 (0.87, 1.09)
Leg pain intensity (0-10) (n= 581), mean (SD) 5.6 (2.3) 4.2 (2.2) 1.32 (1.21, 1.44)
Constant pain symptoms (n= 597) 305 (68.7) 96 (62.8) 1.30 (0.89, 1.91)
Pain described as burning pain (n= 609) 166 (36.7) 55 (35.0) 1.08 (0.74, 1.57)
Duration of back pain symptoms in current episode (n= 607)
< 6 wk 174 (38.6) 44 (28.2) 1
6-12 wk 96 (21.3) 30 (19.2) 0.81 (0.48, 1.37)
> 3mo 181 (40.1) 82 (52.6) 0.59 (0.37, 0.85)
Duration of leg pain symptoms in current episode (n= 583)
< 6 wk 192 (44.2) 59 (39.6) 1
6-12 wk 94 (21.7) 26 (17.5) 1.11 (0.66, 1.87)
> 3mo 148 (34.1) 64 (43.0) 0.71 (0.47, 1.07)
Widespread pain† (n= 592) 171 (38.8) 79 (52.3) 0.58 (0.40, 0.84)
Leg pain worse (n= 607) 251 (55.8) 28 (17.8) 5.81 (3.71, 9.10)
Pain location (n= 609)
Pain below the knee 375 (83.0) 55 (35.0) 9.03 (6.00, 13.60)
Pain in 1 leg 368 (81.4) 89 (56.7) 3.35 (2.26, 4.97)
Limitations in activities, participation and risk of persistent disabling pain
LBLP-related disability (RMDQ) (0-23) (n= 609), mean (SD) 12.9 (5.7) 11.9 (5.7) 1.03 (0.997, 1.06)
Risk of persistent disability due to back pain (STarT Back) (n= 589)
Low risk 53 (12.1) 29 (19.1) 1
Medium risk 212 (48.5) 64 (42.1) 1.81 (1.06, 3.09)
High risk 172 (39.4) 59 (38.8) 1.60 (0.93, 2.74)
Psychological characteristics
Depression (HADS) (n= 609)
Normal (0-7) 295 (65.3) 97 (61.8) 1
Possible (mild) cases (8-10) 82 (18.1) 37 (23.6) 0.73 (0.46, 1.14)
Probable (moderate/severe) cases (≥ 11) 75 (16.6) 23 (14.7) 1.07 (0.64, 1.80)
Anxiety (HADS) (n= 607)
Normal (0-7) 249 (55.2) 67 (43.0) 1
Possible (mild) cases (8-10) 86 (19.1) 34 (21.8) 0.68 (0.42, 1.10)
Probable (moderate/severe) cases (≥ 11) 116 (25.7) 55 (35.3) 0.57 (0.37, 0.86)
Pain self-efficacy (PSEQ, 0-60)‡ (n= 593), mean (SD) 33.3 (14.7) 36.6 (13.9) 0.98 (0.97, 0.997)
Neurological examination findings
Muscle strength§ (n= 608)
5/5 347 (76.8) 156 (100.0) 1
4/5 92 (20.4) 0 —
0 to 3/5 13 (2.9) 0 —
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One of the assumptions underpinning this research is
that the prognosis of patients with NP is considered to be
worse compared with those without. The clinical course of
patients with NP based on s-LANSS was worse than those
without 12 months after initially consulting in primary care
with LBLP, but this was not the case for the 2 other defi-
nitions of NP. The finding that the clinical course is worse in
patients with s-LANSS ≥ 12 is consistent with previous
research using PainDETECT to define NP cases.36 We did
not find that patients with “probable” NP (those patients
with a clinical diagnosis of sciatica with MRI evidence of
NRC) has a worse clinical course than those with “possible”
NP (those more broadly defined by the clinical diagnosis of
sciatica without MRI evidence of NRC).
In patients with a clinical diagnosis of sciatica (with or
without evidence of NRC), the clinical course seemed more
favorable compared with those without (ie, those with a
diagnosis of referred leg pain). There was some evidence
that a higher proportion of patients with a clinical diagnosis
of sciatica (with evidence of NRC) may have received more
targeted care (eg, epidural injection) compared with those
without and compared with those with NP based on
s-LANSS. The absolute difference in the numbers receiving
more targeted care across the 3 definitions was low and the
differences in pain intensity between patients with and
without NP based on a clinical diagnosis of sciatica (with or
without evidence of NRC) were often small with no obvious
clinical relevance. This provides confidence that the course
of patients with sciatica (either with or without evidence of
NRC) was not confounded by treatment in this cohort and
is similar to those without.
The strengths of this research include: (1) the collection
of a broad range of self-report data and clinical assessment
findings from standardized clinical examinations including
MRI scans; (2) the long-term prospective cohort study design
allowed for investigation of the temporal relationship between
NP at baseline and pain intensity over 3 years, this addresses
the limitations of previous research with this patient
population,41 and; (3) the use of mixed-effect models for
repeated measures which take into account fixed effects
(presence or absence of NP at baseline), random effects
(individual patients), interaction between time and the out-
come (pain intensity) and missing data (using likelihood-based
approaches) during model development.
Limitations
Given that a number of characteristics were found to be
very strongly associated with NP (eg, neurological examina-
tion findings were strongly associated with a clinical diagnosis
of sciatica; self-report of burning pain was strongly associated
with NP based on s-LANSS), there is a risk of bias due to the
incorporation of characteristics that were used to determine
cases of NP. Incorporation bias can lead to an overestimation
of the strength of an association between a characteristic and
TABLE 3. (continued)
Neuropathic Pain
(Clinical Diagnosis of Sciatica)
Characteristics*
Yes, n= 452
(74.2%)
No, n= 157
(25.8%)
Unadjusted Odds Ratio
(95% CI)
Reflex (tendon) change (n= 609)
None 341 (75.4) 149 (94.9) 1
Slightly reduced 30 (6.6) 0 —
Significantly reduced or absent 81 (17.9) 8 (5.1) 4.42 (2.09, 9.38)
Sensation to pin-prick in the leg(s) (n= 609)
Normal 226 (50.0) 130 (82.8) 1
Reduction or loss to pin-prick 226 (50.0) 27 (17.2) 4.81 (3.06, 7.6)
Presence of allodynia or hyperalgesia in the leg(s)ǁ (n= 609) 47 (10.4) 11 (7.0) 1.54 (0.78, 3.05)
Neural tension test¶ (any positive test, n= 609) 324 (71.7) 11 (7.0) 33.60 (17.61, 64.10)
Pins and needles in the leg(s) (n= 609) 256 (56.6) 49 (31.2) 2.88 (1.96, 4.23)
Pain affects the color of patients skin (n= 609) 51 (11.3) 16 (10.3) 1.12 (0.62, 2.03)
Neuroimaging
Clear or possible nerve root compression (n= 554) 252 (60.7) 45 (32.4) 3.23 (2.15, 4.85)
Pain medication
No. pain medications# (n= 609)
None 61 (13.5) 23 (14.7) 1
One 177 (39.2) 69 (44.0) 0.97 (0.56, 1.68)
Two or more 214 (47.4) 65 (41.4) 1.24 (0.71, 2.16)
Figures are frequencies (percentages) unless stated otherwise as mean (SD).
Odds ratio (CIs) in italics characteristics associated with neuropathic pain.
*Denominator varies for some characteristics due to missing data or not applicable case.
†Widespread pain was defined as pain present above and below the waist, in the right-hand and left-hand sides of the body and in the axial skeleton.
‡Higher scores on PSEQ reflect stronger self-efficacy beliefs
§Muscle strength was tested according to a 6-point grading scale where; 0. No visible flicker of movement or contraction. 1. Flicker of movement. 2. Full
active movement with gravity counterbalanced. 3. Full active movement against gravity but not applied resistance. 4. Full active movement against gravity and
some applied resistance. 5. Full active movement against gravity and strong resistance.
ǁHyperalgesia is an increased pain response to painful stimuli. Allodynia is pain response to non-painful stimuli (eg, brush strokes).
¶Neural tension tests; straight leg raise, femoral stretch and slump test.
#Pain medications include self-reported history of prescribed medications and those purchased over the counter.
BMI indicates body mass index; CI, confidence intervals; HADS, Hospital Anxiety and Depression Scale; LBLP, leg pain related to back pain; PSEQ, Pain
Self-Efficacy Questionnaire; RMDQ, Roland Morris Disability Questionnaire leg version.
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TABLE 4. Baseline Characteristics of Patients With Neuropathic Pain Based on a Clinical Diagnosis of Sciatica and Evidence of Nerve Root
Compression on MRI
Neuropathic Pain (Clinical Diagnosis of
Sciatica With Clear or Possible Evidence
of Nerve Root Compression)
Characteristics*
Yes, n= 252
(45.5%)
No, n= 302
(54.5%)
Unadjusted Odds Ratio
(95% CI)
Sociodemographic characteristics
Female (n= 554) 137 (54.4) 213 (70.5) 0.50 (0.35, 0.70)
Age (n= 554), mean (SD) 51.9 (13.1) 48.5 (14.2) 1.02 (1.01, 1.03)
Socioeconomic status (n= 540)
Higher managerial, administrative, and professional occupations 53 (21.7) 70 (23.7) 1
Intermediate occupations 65 (26.6) 81 (27.4) 1.06 (0.65, 1.72)
Routine and manual occupations 118 (48.4) 134 (45.3) 1.16 (0.75, 1.80)
Never worked and long-term unemployed 8 (3.3) 11 (3.7) 0.96 (0.36, 2.56)
Smoking status (n= 553)
Never 93 (36.9) 110 (36.5) 1
Ex-smoker 76 (30.2) 93 (30.9) 0.97 (0.64, 1.46)
Current 83 (32.9) 98 (32.6) 1.00 (0.67, 1.50)
BMI (n= 549), mean (SD) (kg/m2) 29.8 (5.9) 29.1 (5.6) 1.02 (0.99, 1.05)
Health status
Self-reported diabetes (n= 554) 20 (7.9) 22 (7.3) 1.10 (0.58, 2.06)
Self-reported general health (n= 553)
Excellent/very good 65 (25.9) 67 (22.0) 1
Good 66 (26.3) 90 (29.8) 0.76 (0.47, 1.20)
Fair 100 (39.8) 122 (40.4) 0.84 (0.55, 1.30)
Poor 20 (8.0) 23 (7.6) 0.90 (0.45, 1.79)
Fatigue (n= 543) 171 (69.5) 209 (70.4) 1.04 (0.72, 1.51)
Sleep difficulties (n= 549) 211 (84.4) 253 (84.6) 1.02 (0.64, 1.62)
Pain characteristics
Back pain intensity (0-10) (n= 543), mean (SD) 5.3 (1.7) 5.3 (1.6) 0.99 (0.89, 1.10)
Leg pain intensity (0-10) (n= 542), mean (SD) 6.0 (2.3) 4.6 (2.3) 1.29 (1.19, 1.40)
Constant pain symptoms (n= 542) 173 (70.0) 202 (68.5) 1.08 (0.75, 1.55)
Pain described as burning pain (n= 554) 87 (34.5) 112 (37.1) 0.89 (0.63, 1.27)
Duration of back pain symptoms in current episode (n= 552)
< 6 wk 97 (38.5) 97 (32.3) 1
6-12 wk 58 (23.0) 58 (19.3) 1.00 (0.63, 1.58)
> 3mo 97 (38.5) 145 (48.3) 0.67 (0.46, 0.98)
Duration of leg pain symptoms in current episode (n= 530)
< 6 wk 106 (43.8) 121 (42.0) 1
6-12 wk 57 (23.6) 54 (18.8) 1.20 (0.76, 1.90)
> 3mo 79 (32.6) 113 (39.2) 0.80 (0.54, 1.18)
Widespread pain† (n= 540) 71 (28.6) 156 (53.4) 0.35 (0.24, 0.50)
Leg pain worse (n= 552) 166 (66.1) 88 (29.2) 4.73 (3.30, 6.77)
Pain location (n= 554)
Pain below the knee 216 (85.7) 178 (58.9) 4.18 (2.74, 6.37)
Pain in 1 leg 210 (83.3) 205 (67.9) 2.37 (1.57, 3.56)
Limitations in activities, participation and risk of persistent disabling pain
LBLP-related disability (RMDQ, 0-23) (n= 554), mean (SD) 13.3 (5.3) 11.9 (5.9) 1.04 (1.02, 1.08)
Risk of persistent disability due to back pain (STarT Back) (n= 530)
Low risk 27 (11.2) 48 (16.3) 1
Medium risk 116 (48.1) 139 (47.1) 1.48 (0.87, 2.53)
High risk 98 (40.7) 108 (36.6) 1.61 (0.94, 2.78)
Psychological characteristics
Depression (HADS) (n= 554)
Normal (0-7) 155 (61.5) 200 (66.2) 1
Possible (mild) cases (8-10) 44 (17.5) 64 (21.2) 0.89 (0.57, 1.37)
Probable (moderate/severe) cases (≥ 11) 53 (21.0) 38 (12.6) 1.80 (1.13, 2.87)
Anxiety (HADS) (n= 553)
Normal (0-7) 137 (54.6) 149 (49.3) 1
Possible (mild) cases (8-10) 50 (19.9) 62 (20.5) 0.88 (0.57, 1.36)
Probable (moderate/severe) cases (≥ 11) 64 (25.5) 91 (30.1) 0.76 (0.52, 1.14)
Pain self-efficacy (PSEQ, 0-60)‡ (n= 542), mean (SD) 32.2 (14.6) 36.1 (14.1) 0.98 (0.97, 0.99)
Neurological examination findings
Muscle strength§ (n= 553)
5/5 191 (75.8) 270 (89.7) 1
(Continued )
Clin J Pain  Volume 36, Number 11, November 2020 Epidemiology of Neuropathic Pain in Back and Leg Pain
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved. www.clinicalpain.com | 821
Copyright r 2020 Wolters Kluwer Health, Inc. All rights reserved.
an outcome, in this research NP being the outcome.42 How-
ever, using 3 accepted NP case definitions, and comparing the
characteristics of patients with NP using each definition, adds
confidence about the characteristics of these patients. Despite
some evidence of incorporation bias, overall there seems to be
limited impact on the main findings of the study.
Implications for Clinical Practice and Research
The implication of using different methods to identify
cases of NP is inevitably variation in prevalence estimates,
characteristics and clinical course; it is not clear what the
implication is in terms of variation in response to treatment.
Given the few differences between patients with sciatica with
or without evidence of NRC on MRI, both at baseline and
in terms of clinical course over 3 years, the clinical impli-
cation of our study is that in the absence of widespread or
progressive neurological deficit, most LBLP patients with a
clinical diagnosis of sciatica (with or without evidence of
NRC) should be treated, at least initially, conservatively.
Imaging should be reserved for those patients for whom the
result is likely to change clinical management. In this
research, patients with NP based on s-LANSS had, on
average, a more severe phenotype compared with those with
NP based on clinical diagnosis, however it is not known if
routine use of s-LANSS in clinical practice would benefit
patients. Our study provides empirical evidence that
questions the usefulness of the hierarchical grading system1
to classify cases of neuropathic LBLP by clinical examina-
tion. Future epidemiological research is needed to inves-
tigate whether characteristics identified from self-report and
routine neurological examination that are thought to be
important for defining cases of neuropathic LBLP can pre-
dict a poor outcome in patients with self-reported signs and
symptoms of NP.
CONCLUSIONS
NP in LBLP patients consulting in primary care is
common, with a prevalence between 48% and 74% depending
on the NP case definition. Many patients with sciatica did not
have NP based on s-LANSS, suggesting that sciatica is not
always a NP condition. Prevalence and characteristics varied
depending on the method used to define NP. At baseline,
LBLP-related morbidities such as depression, anxiety, and
worse general health were more common in patients with NP
based on s-LANSS compared with those with NP based on
clinical diagnosis of sciatica. Evidence of NRC from MRI
increased the certainty of NP but the prognosis of sciatica
patients with or without NRC on MRI, was similar. Our
study shows that it is not the presence of NP per se that is
associated with poor prognosis, but specifically the presence
of self-reported NP. The extent of the improvement in
patients with NP depended on the definition of NP, only the
TABLE 4. (continued)
Neuropathic Pain (Clinical Diagnosis of
Sciatica With Clear or Possible Evidence
of Nerve Root Compression)
Characteristics*
Yes, n= 252
(45.5%)
No, n= 302
(54.5%)
Unadjusted Odds Ratio
(95% CI)
4/5 50 (19.8) 31 (10.3) 2.28 (1.40, 3.70)
0 to 3/5 11 (4.4) 0 —
Reflex (tendon) change (n= 554)
None 169 (67.1) 281 (93.1) 1
Slightly reduced 22 (8.7) 3 (1.0) 12.19 (3.60, 41.4)
Significantly reduced or absent 61 (24.2) 18 (6.0) 5.63 (3.22, 9.86)
Sensation to pin-prick in the leg(s) (n= 554)
Normal 125 (49.6) 199 (65.9) 1
Reduction or loss to pin-prick 127 (50.4) 103 (34.1) 1.96 (1.39, 2.77)
Presence of allodynia or hyperalgesia in the leg(s)ǁ (n= 554) 24 (9.5) 30 (9.9) 0.95 (0.54, 1.68)
Neural tension test¶ (any positive test, n= 554) 185 (73.4) 122 (40.4) 4.07 (2.84, 5.85)
Pins and needles in the leg(s) (n= 554) 137 (54.4) 140 (46.4) 1.38 (0.99, 1.93)
Pain affects the color of patients skin (n= 554) 28 (11.2) 28 (9.3) 1.22 (0.70, 2.12)
Pain medication
No. pain medications# (n= 554)
None 32 (12.7) 37 (12.3) 1
One 97 (38.5) 124 (41.1) 0.90 (0.53, 1.56)
Two or more 123 (48.8) 141 (46.7) 1.01 (0.59, 1.72)
Figures are frequencies (percentages) unless stated otherwise as mean (SD).
Odds ratio (CIs) in italics characteristics associated with neuropathic pain.
*Denominator varies for some characteristics due to missing data or not applicable case.
†Widespread pain was defined as pain present above and below the waist, in the right-hand and left-hand sides of the body and in the axial skeleton.
‡Higher scores on PSEQ reflect stronger self-efficacy beliefs
§Muscle strength was tested according to a 6-point grading scale where; 0. No visible flicker of movement or contraction. 1. Flicker of movement. 2. Full
active movement with gravity counterbalanced. 3. Full active movement against gravity but not applied resistance. 4. Full active movement against gravity and
some applied resistance. 5. Full active movement against gravity and strong resistance.
ǁHyperalgesia is an increased pain response to painful stimuli. Allodynia is pain response to nonpainful stimuli (eg, brush strokes).
¶Neural tension tests; straight leg raise, femoral stretch and slump test.
#Pain medications include self-reported history of prescribed medications and those purchased over the counter.
BMI indicates body mass index; CI, confidence interval; HADS, Hospital Anxiety and Depression Scale; MRI, magnetic resonance imaging; LBLP, leg pain
related to back pain; PSEQ, Pain Self-Efficacy Questionnaire; RMDQ, Roland Morris Disability Questionnaire leg version.
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clinical course of LBLP patients NP defined using s-LANSS
seemed to be worse compared with those without. This study
challenges the commonly held assumptions that the clinical
course of NP is mostly poor.
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